Top Biosimilars companies

The 9 key players our Biosimilars report profiles, and other companies free public records show in this market.

Key players in Biosimilars

In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.

Also active in Biosimilars

Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.

Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

Top trial sponsors in Biosimilars

Companies leading the most active studies found with this market's trial search, worldwide (key players included).

  1. Merck & Co., Inc. 11 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanghai Henlius Biotech 7 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Qilu Pharmaceutical Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Alvotech Swiss AG 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Innovent Biologics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  6. mAbxience Research S.L. 2 active trials on ClinicalTrials.gov (opens in a new tab)
  7. Biocon 2 active trials on ClinicalTrials.gov (opens in a new tab)
  8. Celltrion 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

Biosimilars reports by place

All 33 places for Biosimilars

Get the full Biosimilars report

Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.

Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.